CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

NRx Pharma rises as FDA completes initial review of ketamine product

RegulatoryPositive
AI Analysis

Summary

NRx Pharma's stock rose following FDA completion of initial review of its ketamine product. The regulatory milestone represents progress in the company's development program.

Outcome Details

FDA completed initial review

Importance:5/10
Sentiment:
0.60
FDAregulatoryketamineNRx Pharma
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on August 7, 2026 5:08 PM

Read Original